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Abstract
Cyclodextrins are very important excipients in the pharmaceutical industry. Given the multitude of native and semisynthetic 
cyclodextrin derivatives, there is a need for a rapid and reliable method for the selection of the optimal cyclodextrins for 
further pharmaceutical testing. During our research, circular dichroism (CD) spectroscopy has been successfully used to 
describe the qualitative and quantitative complexation of model compounds with different cyclodextrins. For the appearance 
of a circular dichroism signal, either a chiral or a chirally perturbed chromophore is required. Achiral or racemic compounds 
do not have corresponding circular dichroism spectra and neither do chiral cyclodextrins due to the absence of a chromophore 
group. During complexation of a chromophoric guest molecule, its absorption transition becomes chirally perturbed in the 
proximity of a cyclodextrin molecule and an induced circular dichroism (ICD) signal appears. This phenomenon gives an 
inherent selectivity to the method. The sign and intensity of the induced circular dichroism signal in case of different cyclo-
dextrins provides information about the approximate structure of the complex as well as their stability relative to each other. 
In this study, we report a straightforward induced circular dichroism -based approach for the rapid preselection of the optimal 
cyclodextrin. The distinctive features of the method were demonstrated using five azole-type antifungal drug molecules 
(fluconazole, miconazole, clotrimazole, bifonazole and tioconazole) along with native α-, β-, and γ-cyclodextrins, as well 
as dimethyl-, trimethyl-, carboxymethyl-, hydroxypropyl- and sulfobuthylether-β-cyclodextrins. In addition, with the aid of 
this method, 27 stability constants were determined, amongst which 16 have been unavailable in the literature previously.
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Abbreviations
ACyD  α-Cyclodextrin
BCyD  β-Cyclodextrin
BIZ  Bifonazole
CD  Circular dichroism
CE  Capillary electrophoresis
CLZ  Clotrimazole
CMBCyD  Carboxymethyl-β-cyclodextrin
DMBCyD  Dimethyl-β-cyclodextrin
DMSO  Dimethyl-sulfoxide
ESR  Electron spin resonance
FLZ  Fluconazole
GCyD  γ-Cyclodextrin
HPBCyD  Hydroxypropyl-β-cyclodextrin
HPLC  High performace liquid chromatography
ICD  Induced circular dichroism
IR  Infrared spectroscopy
MIZ  Miconazole
NMR  Nuclear magnetic resonance
NOESY  Nuclear overhauser effect spectroscopy
NP  Normal phase
PS  Phase solubility studies
PSA  Polar surface area
ROESY  Rotating frame nuclear overhauser effect 
spectroscopy
RP  Reverse phase
SBBCyD  Sulfobuthylether-β-cyclodextrin
TIZ  Thioconazole
TLC  Thin layer chromatography
TMBCyD  Trimethyl-β-cyclodextrin
Introduction
Cyclodextrins are being used in numerous areas of the 
industry for a wide range of applications [1–4]. Their main 
property, the ability to form inclusion complexes can aid the 
dissolution of poorly soluble drugs, improve the retention 
of volatile molecules, and enhance chemical stability. How-
ever, despite having numerous advantages, cyclodextrins can 
cause some unexpected issues e.g.: in case of racemic drugs, 
cyclodextrins used in the pharmaceutical industry have dif-
ferent influence on the dissolution of enantiomers from the 
formulation [5, 6].
The selection of the most suitable cyclodextrin for a cer-
tain application can be made by using numerous analytical 
methods such as spectroscopic methods in solutions (UV 
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spectrophotometry, NMR, fluorescence, ESR), separation 
techniques (CE, HPLC, TLC), and electroanalytical methods 
[7, 8]. In case of solid phase samples, IR, Raman, X-ray, 
and thermal methods are the most commonly used, however, 
these approaches are not capable of determining the liquid 
phase (equilibrium) stability constant.
UV spectroscopy is a relatively straightforward method 
having low material needs, but it provides very little infor-
mation about the structure of the complex. In this method, 
the change in the transitions of the chromophore group sig-
nals the formation of a complex [9]. As a result of the forma-
tion of an inclusion complex and the chromophore getting 
into a more apolar environment, the UV absorbance spec-
trum might become more structured than in an aqueous solu-
tion [10]. This interaction might result in either a hyper- or 
hypochromic and hypso- or bathocromic shift of the absorp-
tion spectrum. The two disadvantages of the method are 
that (a) other UV-active compounds may interfere with the 
spectrum, (b) the complexation does not necessarily result 
a characteristic change in the spectrum.
NMR spectroscopy has several advantages. Presence of 
a chromophore in the guest molecule is not required and, 
unlike in CD and UV spectroscopy, it provides information 
about the structure of the complex and it allows for quanti-
fication from the changes in the chemical shifts [11]. This 
method’s drawback is its low sensitivity and the occasional 
need for deuterated solvents. If the guest molecule has low 
solubility, long acquisition times may be needed for achiev-
ing adequate signal–noise ratios in the case of 2D NOESY or 
ROESY techniques, which are necessary in structure analy-
sis. The use of other solvents might be required to ensure 
the proper concentration of the compound. However, this 
additional solvent might affect the stability and the structure 
of the complex. In case of native cyclodextrins—due to their 
symmetry—the interpretation of the spectra can be simple, 
but in the case of modified cyclodextrins, the presence of 
structural isomers (different substitution degree) complicates 
the structural analysis.
The biggest advantage of fluorescence spectroscopy is the 
quantum yield effect, making it more sensitive and usable in 
a wider concentration range, compared to other techniques. 
It has to be noted that the signal intensity, despite being in 
correlation with the concentration, is not linear [12]. When 
using modified cyclodextrins containing fluorophore groups, 
the fluorescence spectrum changes due to interactions with 
the guest molecule. Commonly, the fluorophore is displaced 
from the cavity by the guest molecule in a competitive pro-
cess. Based on this principle, cyclodextrins can be applied 
as molecular sensors [13].
Capillary electrophoresis requires small quantities of 
material, but either the guest molecule or the cyclodex-
trin must have a charged functional group. Neutral mol-
ecules and cyclodextrins cannot be tested directly. If the 
cyclodextrin is dissolved in the mobile phase, it might 
function as a chiral selector in case of enantiomer pairs 
[14].
HPLC methods are not restricted to charged molecules 
and apply cyclodextrins two ways: first, the cyclodextrin is 
covalently bonded to the solid phase [15]; second, the cyclo-
dextrin is dissolved in the mobile phase [16].
When applying covalently bonded cyclodextrins, the 
separation can be performed using normal (NP) or reverse 
phase (RP) mode [17]. Testing different cyclodextrins 
require purchasing a column of each type. This is costly and 
time-consuming, especially if optimisation of the chroma-
tographic parameters also requires addressing mobile phase 
composition and temperature parameters.
When cyclodextrins are dissolved in the mobile phase, a 
simple RP column (RP2–RP18) may be used to identify the 
optimal cyclodextrin by varying the cyclodextrin concen-
tration and analysing the reduction in the retention time of 
the guest molecule. With this method, an apparent stability 
constant can be determined as well [18]. Problems posed by 
this technique are high costs, because for method optimisa-
tion large quantities of cyclodextrins might be required. In 
addition, optimization can be a lengthy procedure. Similarly, 
to capillary electrophoresis, attaining enantiomer selectivity 
can be set as an aim [19, 20].
Alongside the methods mentioned above, circular dichro-
ism can come to mind as a good alternative. Its sensitivity 
and material needs are on par with UV spectroscopy but it 
provides more detailed structural information. Upon anal-
ysis of CD spectra, the formation of inclusion complexes 
can be confirmed and the structure of the complex can be 
assessed using theoretical calculations. Another benefit of 
this method is that, like UV spectroscopy, it can rapidly 
provide results, resulting in shorter experiment times. Fur-
thermore, CD spectroscopy is less expensive than NMR or 
separation techniques.
The limiting factor of the method is the necessity of a 
chromophore on the guest molecule, which needs to be able 
to interact with the cyclodextrin to produce an induced CD 
signal (ICD) [21]. The appearance of this ICD signal in 
the region of the absorption bands is a definite proof of the 
complex formation. The sign and intensity of the ICD band, 
supplemented with theoretical calculations give opportuni-
ties for further estimations regarding the complex structure 
[22–24]. ICD spectra can be used to distinguish between 
cyclodextrins having different degrees of substitution [25]. 
In case of achiral or racemic substances when only the com-
plex is CD active, it is possible to estimate the equilibrium 
(stability) constant, because the intensity of the ICD signal 
will be proportional to the complex concentration. Similar 
selectivity can only be achieved using NMR [26].
For the calculations, the following need to be taken into 
account:
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The equilibrium can be described with Eq. (1) in case of 
a 1:1 complex:
where  Ke is the equilibrium constant,  [H]e is the equilibrium 
concentration of the host,  [G]e is the equilibrium concen-
tration of the guest and [HG] is the concentration of the 
complex.
The equilibrium concentrations can be expressed as a 
function of the total concentrations as following
where  [H]T is the total concentration of the host and  [G]T is 
the total concentration of the guest.
Replacing the equilibrium concentration of the host and 
the guest in Eq. (1) with the expressions from Eqs. (2) and 
(3), it can be written as:
Expressing [HG] from Eq.  (4) leads to a quadratic 
equation:
With the condition  [G]T ≥ [HG] ≥ 0, the quadratic equa-
tion gives only the solution of Eq. (5) and the other roots 
does not need to be taken into consideration.
Keeping the concentration of the guest molecule constant 
and changing the concentration of the cyclodextrins one 
can obtain a saturation curve depending on the cyclodextrin 
excess and stability constant. The measured ellipticity (θ) 
correlates only with the concentration of the complex ([HG]) 
and at the maximum of the ellipticity signal true to Eq. (6):
The stability constant can be calculated by using nonlin-
ear parameter fitting for Eqs. (5) and (6)
Using these calculations, the stability constants of 
drug–cyclodextrin interactions can easily be compared and 
the most suitable cyclodextrin may be selected for the pur-
pose in question. As a drawback, it needs to be mentioned 
that the acquired ICD signal has low intensity sometimes, 
resulting in disadvantageous signal–noise ratios in the case 
of low-stability complexes (logK < 2). Light scattering can 
(1)Ke =
[HG]
[H]e × [G]e
(2)for the host: [H]e = [H]T − [HG]
(3)for the guest: [G]e = [G]T − [HG]
(4)Ke =
[HG](
[H]T − [HG]
)
× (
[
G]T − [HG]
)
(5)
[HG] =
[
G]T+
[
H]T +
1
K
−
√([
G]T+
[
H]T +
1
K
)2
− 4
[
G]T
[
H]T
2
(6)θMAX ≈ [G]T = [HG]
(7)θ
θMAX
=
[HG]
[G]T
→ θ =
θMAX
[G]T
× [HG]
be another occurring problem. It can be detected from the 
UV spectra measured along the CD, outside of the absorp-
tion region, the increase in the baseline signals the pres-
ence of solid particles. While these can be removed from the 
solutions by filtration, accurate calculations cannot be made 
from the ellipticity data acquired. In racemic substances, the 
stability of the two diastereomer complexes are different, 
so the calculated data is only average or apparent constant.
To demonstrate the method’s capability five antifungal 
azole molecules were tested with different cyclodextrins.
Materials and methods
The following materials are products of Cyclolab 
Ltd. (Budapest, Hungary): α-cyclodextrin (ACyD); 
β-cyclodextr in (BCyD); γ-cyclodextr in (GCyD), 
heptakis(2,6-di-O-methyl)-β-cyclodextrin (DMBCyD); 
(2-hydroxypropyl)-β-cyclodextrin (HPBCyD) (D.S~5,5); 
heptakis(2,3,6-tri-O-methyl)-β-cyclodextrin (TMBCyD); 
β-cyclodextrin sulfobutyl ether sodium salt (SBBCyD) 
(D.S~6,3); carboxymethyl-β-cyclodextrin sodium salt 
(D.S~3,5) (CMBCyD); fluconazole [2-(2,4-difluorophenyl)-
1,3-bis(1H-1,2,4-triazol-1-yl)propan-2-ol], miconazole 
[(RS)-1-(2-(2,4-dichlorobenzyloxy)-2-(2,4-dichlorophenyl)
ethyl)-1H-imidazole] and bifonazole [(RS)-1-[Phenyl(4-
phenylphenyl) methyl]-1H-imidazole] were pharmaco-
poeial grade (Ph. Eur. 7.8) products of Sandoz (Budapest, 
Hungary). Clotrimazole [1-[(2-chlorophenyl)- (diphenyl)
methyl]-1H-imidazole] and tioconazole [(RS)-1-[2-[(2-
Chloro-3-thienyl)methoxy]-2-(2,4-dichlorophenyl)ethyl]-
1H-imidazole] as well as the dimethyl sulfoxide (DMSO) 
used to dissolve the drug were purchased from Sigma-
Aldrich (Budapest, Hungary). For the structures of model 
compounds see Supplement Fig. S1. CD and UV experi-
ments were performed on a Jasco J-720 spectropolarimeter 
(Jasco Ltd., Tokyo, Japan) in Jasco and Hellma cylindrical 
cuvettes with pathlengths ranging from 1 to 20 mm. The 
nonlinear parameter fitting was performed with Origin 8.0.
Drugs were dissolved in DMSO to form 0.1 M stock 
solutions, which were further diluted with distilled water to 
0.0016 M for the experiments. Cyclodextrin stock solutions 
were 0.016 M in water. Experimental cyclodextrin (CyD)-
drug solutions were mixed with the following concentration 
ratios: 0:1, 0.5:1, 1:1, 2:1, 5:1 and 10:1. In certain occasions, 
20:1 and 50:1 ratio were also prepared. To promote the solu-
bility of the drugs, 5 µl 2 M HCl was used (pH ~ 2).
First, solutions containing only the drugs were meas-
ured. For each experiment, the cuvette was chosen so the 
absorption at the absorption peak would not exceed 2. All 
the spectra were registered with the following parameters: 
scan speed: 50 nm/min; slit: 2 nm; response (D.I.T.): 2 s; 
accumulation 3–5 depending on the signal–noise ratio.
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Results and discussion
Fluconazole
Based on literature data, the logK stability value of the com-
plex changes depending on the protonation of the molecule. 
In case of β-cyclodextrin complexes, the logK of the posi-
tively charged form is 1.03, while for the unionised form it 
is 1.97 [27] or 1.83 [28]. At pH ~ 2, the positively charged 
form is the dominant. Our previous, unpublished data showed 
1.13 (positively charged) and a 1.64 (neutral) logK for HPB-
CyD, 1.9 (charged) and 1.72 (neutral) for SBBCyD. During 
experiments ICD spectra could not be registered; see spectra 
in Supplement Fig. S2. Low logK values as well as low logP 
and high polar surface area (PSA) of FLZ is a possible expla-
nation for this, based on previous literature [29] these two 
physical parameters, as well as the geometry of the molecule 
are the main factors affecting cyclodextrin stability constants.
Bifonazole
As a result of the intensive aromatic band at ~ 250 nm of 
the biphenyl group in BIZ, the experiments were performed 
using 0.2 cm cuvettes as described in “Materials and meth-
ods” section. Figure 1 presents the measured CD signal at 
the highest ICD band as the function of CyD concentration. 
In case of ACyD at 5 and 10 time CyD excess precipitation 
occurred and the constant was calculated from fewer points. 
In case of BCyD, DMBCyD, GCyD, and CMBCyD, at large 
(10×) excess, the ellipticity values decreased. This signals 
the formation of a complex with a different stoichiometry 
in addition to 1:1. There is a possibility of the complexa-
tion of both the biphenyl and the phenyl group. Calculations 
were made without taking the last point(s) into considera-
tion. In addition to changes in the  K1:1 ratio, the regression 
coefficient  (R2) also improved (Table 1). Constants for 
BCyD and CMBCyD became identical as can be expected 
from the slope of the curves in the first section. 
Figure 2 shows the CD (Fig. 2a) and UV (Fig. 2b) spec-
tra of BIZ, BIZ–BCyD, BIZ–SBBCyD and BIZ–GCyD 
complexes. While in the UV spectra of BIZ–BCyD and 
BIZ–SBBCyD a strong hypochromic and minimal hyp-
sochromic effect can be observed compared to the spec-
trum of BIZ, BIZ–GCyD showed a bato- and hypochromic 
UV shift and a new smaller intensity CD band appeared 
at 235 nm. Another difference in case of GCyD is the CD 
maximum appearing as higher wavelength (269) than in UV 
(258.4 nm), while BCyD and SBBCyD show a slight hyp-
sochromic shift (255.6–254.6 nm). According to Table 1, 
the BIZ-SBBCyD complex has the highest stability value 
as a result of the electrostatic interaction between the proto-
nated imidazole and negatively charged sulfobutyl groups. 
UV spectra of BCyD and SBBCyD at same cyclodextrin 
excess concentrations do not differ significantly, making it 
impossible to distinguish between the two; however, the dif-
ference in CD spectra proves their different complexation. In 
the case of SBBCyD the ionic interaction has influence on 
the depth of immersion and this fact results in significant dif-
ference between the BCyD and SBBCyD spectra. The GCyD 
shows notable bathochromic shift and relative low intensity. 
This fact allows to presume that the biphenyl chromophore 
is not parallel with the cyclodextrin’s axis or there is space 
enough to immerse a phenyl group simultaneously.
Clotrimazole
PSA value of CLZ is similar to BIZ, however the logP is 
higher as a result of the chlorophenyl group. Based on these 
parameters, K values are expected to be similar but the 
geometry of the molecule is different. CLZ is more compact, 
resulting in lower conformational freedom, also due to its 
molecular shape it is not expected to sink into the cavity like 
the biphenyl or phenyl group of BIZ.
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Fig. 1  Ellipticity of the BIZ:CyD complexes at increasing CyD con-
centrations ([BIZ] = 1.6 mmol/L)
Table 1  BIZ–CyD complex stability values and regression coeffi-
cients
CyD LogK1:1  (M−1) and 
 (R2) (all data)
LogK1:1  (M−1) and  (R2) 
(without the last data 
point)
ACyD 2.74 (0.9966)
TMBCyD 2.95 (0.9975)
BCyD 3.43 (0.9898) 3.40 (0.9964)
CMBCyD 3.59 (0.9861) 3.40 (0.9950)
GCyD 4.18 (0.9565) 4.04 (0.9636)
DMBCyD 4.39 (0.9911) 4.21 (0.9986)
HPBCyD 4.46 (0.9957)
SBBCyD 4.72 (0.9962)
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In the case of CLZ, structural information cannot be 
gained from the UV spectra, neither the structural, neither 
intensity changes appear after CyD complexation; see Sup-
plement Fig. S3. If observing simply the UV absorbance as a 
function of cyclodextrin concentration changes, the conclu-
sion might be false, because there are no significant changes.
In contrast, CD spectra are highly informative. They can 
be divided into three groups (Fig. 3) based on their sign. Fig-
ure 3a presents two structured spectra with dominantly nega-
tive ICD bands, but different intensity. Similarly, to BIZ, 
Fig. 3a also presents two positive ICD bands that are less 
structured than the negative bands on same figure and the 
alternating spectra of Fig. 3b, but are more informative than 
in case of BIZ. Figure 3b also shows structured spectra, how-
ever, they contain alternating positive and negative bands. 
These characteristic changes—using Kodaka–Harata rules 
[22, 24]—allow us to estimate inner–outer binding. Taking 
into consideration the length of the substituents and using 
the Kodaka–Harata rules, it can be assumed that the strong 
ionic interaction between the protonated imidazole ring and 
the negatively charged sulfobutyl side chain, does not allow 
the immersion of the molecule into the cavity. The shorter 
side chain (e.g. CMBCyD and HPBCyD) results in alternat-
ing positive–negative bands which means deeper immersion. 
BCyD and DMBCyD has only positive ICD bands because 
there is no steric inhibition.
Based on the ICD sign, intensity, and molecular geome-
try, it can be estimated that in case of SBBCyD–CLZ com-
plex, CLZ is dominantly outside the cavity, only a small 
part of the molecule sinks in it. The sharply differentiated 
transitions assume a lower conformational freedom state. 
Outer binding is also supported by BCyD’s cavity volume 
(~ 307 Å3) and CLZ’s van der Waals volume (~ 309.52 Å3) 
being close numbers, thus the whole molecule is unable 
to fit into the cavity. This theory is supported by Pradines 
et al. [34]. Their NMR experiments and quantum chemical 
Fig. 2  CD (a) and UV (b) spectra of BIZ (black), BIZ–BCyD 
(red), BIZ–GCyD (blue) and BIZ–SBBCyD (green) complexes 
([BIZ]  =  1.6  mmol/L) The cyclodextrins are in ×5 molar excess. 
(Color figure online)
Fig. 3  Different types of 
CLZ–CyD ICD spectra 
([CLZ] = 1.6 mmol/L). a Red—
TMBCyD, black–SBBCyD, 
orange—BCyD, aqua—DMB-
CyD. b Green—CMBCyD, 
blue—HPBCyD. The cyclodex-
trins are in ×10 molar excess. 
(Color figure online)
Journal of Inclusion Phenomena and Macrocyclic Chemistry 
1 3
calculations point out that only one substituent, the phenyl 
or chloro-phenyl moiety fits alternatively into the cavity of 
the cyclodextrin. This fact has to be taken into considera-
tion with substituted β-cyclodextrins as well. As a result, 
calculated stability values in Table 2 are lower than BIZ’s 
values. Due to precipitation, ACyD and GCyD constants 
could not be calculated. Figure 4 contains GCyD data only 
as briefs. Due to GCyD having a larger cavity, formation 
of inclusion complexes is possible, however, if during the 
excitation, the electrical dipole moment resultant is not 
parallel or perpendicular to the cyclodextrin’s axis, the 
ICD sign becomes questionable. Because of precipitation, 
ACyD spectra could not be quantitatively evaluated, they 
showed a weak negative ICD signal. Since ACyD has an 
even smaller cavity than BCyD, a weak outer biding is 
highly likely.
Miconazole
PSA value of MIZ (Table 3) is slightly higher than BIZ 
or CLZ, while the logP value is close to BIZ. Structural 
features allow the molecule to have higher conformational 
freedom than either CLZ or BIZ. Based on molecular 
properties, the complex stability values are expected to be 
between the two molecules discussed earlier. The native UV 
spectrum maxima of miconazole—due to the dichlorophe-
nyl substituent—appear at higher wavelengths in compari-
son with BIZ. The UV spectra of MIZ-CyD (Fig. 5b) com-
plexes show a hyper- and batochromic shift compared to the 
original molecule and intensity changes are highly similar, 
making it impossible to distinguish between them with UV 
spectroscopy only. The only exception is GCyD, where the 
shift effects are stronger. Unlike on the previous occasions, 
characteristic benzoyl bands appear in the spectra. While 
the UV spectra of MIZ-BCyD and MIZ-SBBCyD almost 
fully overlap, their CD spectra’s intensity and shape show 
Table 2  CLZ–CyD complex-stability values and regression coeffi-
cients
CyD LogK1:1  (M−1) and  R2
ACyD –
GCyD –
TMBCyD 1.48 (0.9996)
HPBCyD 2.09 (0.9966)
BCyD 2.65 (0.9861)
CMBCyD 2.91 (0.9802)
DMBCyD 3.23 (0.9924)
SBBCyD 3.47 (0.9972)
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Fig. 4  Ellipticity of the CLZ:CyD complexes at increasing CyD con-
centrations ([CLZ] = 1.6 mmol/L)
Table 3  Molecular parameters and logarithm of stability constant 
 (M−1) of azole–βCyD complexes
a Source http://www.molin spira tion.com/servi ces/prope rties .html 
(16.01.2019) [33]
Compound Polar 
surface area 
(Å2)a
LogP (octanol/
H2O)
LogK(1:1) βCyD CD
Fluconazole 81.65 0.41 [30] 1.03 [24]
Miconazole 27.05 4.50 [31] 2.70
Tioconazole 27.05 5.12 [32] 3.85
Bifonazole 17.82 4.77 [32] 3.40
Clotrimazole 17.82 5.20 [32] 2.65
Fig. 5  CD (a) and UV (b) spectra of MIZ (black), MIZ–BCyD (red), 
MIZ–SBBCyD (green) and MIZ–GCyD (blue). The MIZ:CyD con-
centration ratio is 1:10 ([MIZ] = 1.6 mmol/L). (Color figure online)
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significant differences (Fig. 5a). This difference may be in 
association with the immersion depth and the assumption 
based on the Kodaka–Harata rules [22, 24].
Figure 6 shows the ellipticity values read at the maxi-
mum of the most intensive transitions at increasing CyD 
concentrations; Table 4 presents the calculated stability 
values and regression coefficients. Most probably due to 
steric reasons, MIZ-SBBCyD was not the most stable, the 
constants acquired for both GCyD and DMBCyD com-
plexes are higher. Higher conformational freedom and the 
size of the dichlorophenyl group can be listed among the 
steric reasons. At the beginning of the curves on Fig. 6, 
DMBCyD’s ellipticity (cyan) changes the most, giving the 
highest stability value. It is followed by GCyD, having 
the second highest value. Based on our experience, the 
complex stability can be estimated from the slope of the 
curve’s first part and equilibrium concentration, but not 
from the absolute intensity data.
Tioconazole
The structure of tioconazole resembles miconazole, the main 
difference being the replacement of the dichlorophenyl group 
with chlorothiophene. This change does not affect the PSA 
value but increases the lipophilicity slightly. The other differ-
ence is the size of the substituents; chlorothiophene is smaller 
than the dichlorophenyl group. The most intensive transition 
at the highest wavelength originates from the dichlorophenyl 
substituent as well as in case of MIZ. Comparing stability val-
ues, tioconazole’s are higher (Table 5), the reason behind can 
be found in the structure and molecular parameters following 
from it. Despite the structural similarity, some differences 
can be found between MIZ– and TIZ–CyD complexes. First, 
the sign of the ellipticity of GCyD complexes: MIZ has a 
positive, while TIZ has a negative band, which suggests a dif-
ferent orientation of the chromophore in the complex (Fig. 7). 
In case of CMBCyD, the ellipticity decreases at the highest 
cyclodextrin concentration, which proposes the formation of 
a complex with different stoichiometry than 1:1. Skipping the 
last two data points, the constant value decreases while  R2 
improves, however, the goodness of fit still does not reach the 
values calculated for the rest of the complexes. Tioconazole 
has a quite disadvantageous UV spectrum, it has only two 
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Fig. 6  Ellipticity of the MIZ:CyD complexes at increasing CyD con-
centrations ([MIZ] = 1.6 mmol/L)
Table 4  MIZ–CyD complex-stability values and regression coeffi-
cients
CyD LogK1:1  (M−1) and  R2
BCyD 2.70 (0.9943)
HPBCyD 2.71 (0.9949)
CMBCyD 2.96 (0.9963)
SBBCyD 3.18 (0.9925)
GCyD 3.37 (0.9969)
DMBCyD 3.68 (0.9995)
Table 5  TIZ–CyD complex-stability values and regression coeffi-
cients
a Last two data points omitted
CyD LogK1:1  (M−1) and  R2
ACyD 3.12 (0.9877)
BCyD 3.18 (0.9925)
CMBCyD 3.25 (0.9362)
2.85a (0.9783a)
HPBCyD 3.30 (0.9998)
GCyD 3.71 (0.9921)
DMBCyD 3.86 (0.9997)
SBBCyD 3.97 (0.9996)
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Fig. 7  Ellipticity of the TIZ:CyD complexes at increasing CyD con-
centrations ([TIZ] = 1.6 mmol/L)
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relatively flat peaks, one at 270.7 (shoulder only) the other 
at 279.5 nm (peak). Minor batochromic and hyperchromic 
shifts occur after cyclodextrin complexation, but the differ-
ences vary with the CyD used (see Supplement Fig. S4). ICD 
spectra always showed well-separated bands. These spectra 
can be classified into three groups (Fig. 8). ACyD and BCyD 
feature positive, closely equal intensity bands at both absorp-
tion regions. HPBCyD, DMBCyD, CMBCyD and SBBCyD 
are described by slight batochromic shift and increased inten-
sity of the band at higher wavelengths, while GCyD showed 
strong batochromic shift and negative ICD bands (Fig. 8).
Summary
Circular dichroism is a suitable method for investigating 
the interaction of guest molecules with cyclodextrins. The 
appearance of the ICD signal is a matchless and strong proof 
of a non-covalent host–guest type inclusion complex for-
mation. Such unambiguous, straightaway and fast evidence 
cannot be achieved by any other method. The intensity, sign, 
structure and shifts of spectral bands along with physico-
chemical properties and literature data allow for estimation 
of the complex structure. The CD spectroscopy may be an 
alternative to phase solubility studies also, because the UV 
and CD signals are measured in parallel, so the informa-
tion about the increased solubility and the complexed guest 
concentration can be measured on two channels. A further 
possibility is the use of a third channel, if the CD spectropo-
larimeter is equipped with a fluorescent detector.
Taking into consideration that both the imidazole and 
triazole chromophores absorption maxima appear under 
240 nm, the signals must arise from the phenyl groups. The 
 LB band of a phenyl group have maximum about 250 nm, 
which is highly affected by several factors e.g. solvents, sub-
stituents, and the homo- and hetero-molecular interactions. 
The fine structure of this transition is affected by the polar-
ity of its surroundings and by conformational freedom. The 
complexation ensures a more apolar media in the cavity of 
the cyclodextrin for the lipophilic part(s) of the molecule; 
therefore the ΔG (Gibbs free energy) and ΔS (entropy) 
changes are advantageous in regard to complex formation. 
These facts allow to assume that the apolar phenyl or substi-
tuted phenyl chromophores take part dominantly in the com-
plexation. In the case of MIZ and TIZ the higher absorption 
wavelengths are associated with the dichlorophenyl moieties.
The method is also useful for calculating stability con-
stants based on simple equations. The simplicity of the cal-
culation follows from the selectivity of the method, because 
only the complex gives signal, while other methods give the 
average signal of the different coexisting species (free and 
complexed particles). A very stable complex may be unfa-
vourable from the point of view of drug release. Comparing 
the obtained values with each other, it may provide informa-
tion on which cyclodextrins are suitable for complexation, 
however the value of the stability constant should not be the 
only basis for the decision.
Some other spectral properties may also informative, e.g. 
elevated baseline in both the CD- and UV-spectra signal the 
Fig. 8  CD spectra of TIZ (black), TIZ–ACyD (red), TIZ–HPBCyD 
(blue) and TIZ–GCyD (green) complexes at ×2 molar excess of 
CyD-s ([TIZ] = 1.6 mmol/L). (Color figure online)
Table 6  Summary and comparison of logK values are calculated and collected from the literature
Fluconazole Bifonazole Clotrimazole Miconazole Tioconazole
Meas Lit Meas Lit Meas Lit Meas Lit Meas Lit
ACyD – 2.74 – – – – 3.12 –
BCyD – 1.03 [27] (NMR) 3.40 3.34–3.52 [39] (CE) 2.65 2.66 [41] (PS) 2.70 2.91 [41] (PS) 3.18 3.12 [43] (CE)
DMBCyD – 4.21 – 3.23 – 3.68 – 3.86 3.84 [43] (CE)
TMBCyD – 2.95 3.13–3.26 [39] (CE) 1.48 – – – – –
HPBCyD – 1.13 [27] (NMR) 4.46 3.66 [38] (NMR) 2.09 2.65 [40] (PS) 2.71 2.56 [42] (PS)
2.41 [44] (PS)
3.30 2.86 [43] (CE)
SBBCyD – 1.90 [27] (NMR) 4.72 3.94 [38] (NMR) 3.47 – 3.18 – 3.97 –
CMBCyD – 3.40 – 2.91 – 2.96 – 3.25 –
GCyD – 4.04 6.45 (1:2) [38] (NMR) – 3.04 [37] (PS) 3.37 – 3.71 –
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appearance of colloidal particles, so the method is capable 
of detecting poorly soluble complexes. It needs mention-
ing that our results are based on presuming the existence of 
only 1:1 stoichiometry as well as not taking into considera-
tion the different stability of enantiomers in case of racemic 
substances. If more detailed complex structure is required, 
then the use of multiple methods can provide us with more 
accurate data [35, 36], however it was not the aim of this 
research. Table 6 summarizes the calculated logK values 
and gives a comparison with data mined from the literature.
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